EMA — authorised 20 January 2012
- Application: EMEA/H/C/002096
- Marketing authorisation holder: Allos Therapeutics Ltd
- Local brand name: Folotyn
- Indication: treatment of peripheral T-cell lymphoma
- Pathway: orphan
- Status: rejected
🇪🇺 Folotyn in European Union
EMA authorised Folotyn on 20 January 2012
Marketing authorisation
Folotyn in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in European Union
Frequently asked questions
Is Folotyn approved in European Union?
Yes. EMA authorised it on 20 January 2012.
Who is the marketing authorisation holder for Folotyn in European Union?
Allos Therapeutics Ltd holds the EU marketing authorisation.